C. Manegold

Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

Martin Reck, Joachim von Pawel, Petr Zatloukal et al. · Annals of Oncology · 2010 · 644 citations · Full text

Medicine, Oncology, Pharmacology +11

Clinical and biochemical features of aromatic L-amino acid decarboxylase deficiency

Louis‐Daniel Brun, Lock Hock Ngu, Wee Teik Keng et al. · Neurology · 2010 · 225 citations

Medicine, Neurology, Neuroscience +17

Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975

Fabio Efficace, Andrew Bottomley, Egbert F. Smit et al. · Annals of Oncology · 2006 · 184 citations

Medicine, Oncology, Palliative Care +11

Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704

C. Manegold, Joachim von Pawel, Petr Zatloukal et al. · Journal of Clinical Oncology · 2007 · 167 citations

Medicine, Oncology, Pharmacology +11

Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma

C. Manegold, James T. Symanowski, U. Gatzemeier et al. · Annals of Oncology · 2005 · 163 citations

Medicine, Oncology, Pharmacology +13